Lake Street Maintains Buy on AEON Biopharma, Raises Price Target to $2

Benzinga Newsdesk www.benzinga.com Positive 72.7%

Neg 0% Neu 0% Pos 72.7%

Lake Street analyst Thomas Flaten maintains AEON Biopharma (AMEX:AEON) with a Buy and raises the price target from $1 to $2.